中国和印度正逐渐成为生命科学产业的重要参与者。两国不仅拥有丰富的顶尖人才，产业资源也在快速提升。同时，两国既是药品、医疗器械和诊断试剂的重要现有及潜在市场，预计在不久的将来还将成为创新的重要来源。 本专题讨论将深入探讨中印两国蕴藏的重大机遇，不仅涉及向两国拓展业务，更聚焦于与源自中印的创新企业开展合作。
主持人：
- 大卫·A·查拉普，福里尔·拉德纳律师事务所特别顾问
讨论嘉宾：
- 斯蒂芬·A·本特，合伙人，富乐律师事务所
- 弗里德海姆·布洛贝尔 博士，总裁、首席执行官、董事，赛克隆制药公司
- 金·坎达尔 博士，Domain Associates公司首席顾问
- 桑杰·舒克拉 医学博士、理学硕士，RxMD首席执行官
相关见解
January 6, 2026
Foley Viewpoints
Shifting Enforcement Priorities at the CFTC and the SEC
Under the new administration, priorities have shifted at the Commodity Futures Trading Commission and the Securities and Exchange Commission, particularly with the enforcement divisions at both agencies — which had faced widespread internal and external criticism. Both the CFTC and SEC are undergoing structural changes as a shift away from regulation through enforcement. This article discusses these developments in detail.
January 5, 2026
Foley Viewpoints
Fred Ridley showcased in Sports Business Journal’s “The 125 Most Influential in Sports Business of the Past 25 Years
Fred Ridley took over as chairman of Augusta National Golf Club in the fall of 2017, and in those short eight years, he has enacted…
January 5, 2026
Labor & Employment Law Perspectives
New Year, New Rules for Applying for H-1B Visas
On December 23, 2025, the U.S. Department of Homeland Security (DHS) issued a Final Rule to amend the process by which the government…